Engineered donor graft (donor cells treated in a lab) for people getting allogeneic (cells from a donor) blood or marrow transplant (BMT) to treat blood cancerPrint
18 - 65
Clinical Trial Goal
You may be able to join this trial if you:
- Are 18 – 65 years old
- Have one of the following diseases:
- Acute lymphocytic leukemia (ALL) that has gotten better after treatment (complete remission)
- Acute myeloid leukemia (AML) in complete remission
- Mixed phenotype leukemia in complete remission
- Myelodysplastic syndrome (MDS) that doctors consider high risk
- Are able to get an allogeneic BMT with intense (myeloablative) chemotherapy (chemo). Your doctor can tell you this
- Have not had an allogeneic BMT
- Agree to have other standard tests done to see if you can be in the clinical trial
First, you’ll be treated with standard myeloablative chemo to prepare your body for transplant.
On transplant day, the treated blood-forming cells from your donor will be given to you as an intravenous (IV) infusion.
You’ll also get standard treatment to prevent GVHD.
You’ll have biopsies to see how well treatment is working. After treatment, the clinical trial doctors will check your health for 1 year.
The Food and Drug Administration (FDA) not yet approved this type of engineered donor graft in an allogeneic BMT to treat blood cancer.
James S McClellan, MD, PhD, 1-530-414-9743, email@example.com
City of HopeRecruiting
Amandeep Salhotra, MD
Stanford Health CareRecruiting
Robert Lowsky, MD
Mehrdad Abedi, MD
Edmund Waller, MD
The University of Kansas HospitalRecruiting
Kansas City, Kansas
Joseph McGuirk, MD
Ohio State UniversityRecruiting
Ayman Saad, MD
University of Texas MD Anderson Cancer CenterRecruiting
Samer Srour, MD
Froedtert Memorial Lutheran HospitalWithdrawn
lead: Orca Biosystems, Inc.
NCT03802695. First posted on 1/14/19